BE2010C018I2 - - Google Patents

Download PDF

Info

Publication number
BE2010C018I2
BE2010C018I2 BE2010C018C BE2010C018C BE2010C018I2 BE 2010C018 I2 BE2010C018 I2 BE 2010C018I2 BE 2010C018 C BE2010C018 C BE 2010C018C BE 2010C018 C BE2010C018 C BE 2010C018C BE 2010C018 I2 BE2010C018 I2 BE 2010C018I2
Authority
BE
Belgium
Application number
BE2010C018C
Other languages
French (fr)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26901947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2010C018(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BE2010C018I2 publication Critical patent/BE2010C018I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/48Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Vehicle Body Suspensions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Information Transfer Systems (AREA)
  • Hard Magnetic Materials (AREA)
BE2010C018C 2000-05-25 2010-04-13 BE2010C018I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20708400P 2000-05-25 2000-05-25
US22892900P 2000-08-30 2000-08-30
PCT/US2001/016863 WO2001089457A2 (en) 2000-05-25 2001-05-24 Thrombopoietin mimetics

Publications (1)

Publication Number Publication Date
BE2010C018I2 true BE2010C018I2 (nl) 2020-08-20

Family

ID=26901947

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2010C018C BE2010C018I2 (nl) 2000-05-25 2010-04-13

Country Status (30)

Country Link
US (9) US7160870B2 (nl)
EP (3) EP1864981B8 (nl)
JP (2) JP3813875B2 (nl)
KR (2) KR100798568B1 (nl)
CN (4) CN101343250B (nl)
AR (2) AR030696A1 (nl)
AT (2) ATE374772T1 (nl)
AU (2) AU2001274938C1 (nl)
BE (1) BE2010C018I2 (nl)
BR (1) BRPI0111116B8 (nl)
CA (1) CA2411468C (nl)
CY (4) CY2010012I2 (nl)
CZ (1) CZ303176B6 (nl)
DE (4) DE60140224D1 (nl)
DK (3) DK1864981T3 (nl)
ES (3) ES2328179T3 (nl)
FR (1) FR10C0034I2 (nl)
HK (4) HK1113057A1 (nl)
HU (3) HU230487B1 (nl)
IL (5) IL152988A0 (nl)
LU (1) LU91681I2 (nl)
MX (1) MXPA02011621A (nl)
MY (1) MY136707A (nl)
NO (3) NO324246B1 (nl)
NZ (2) NZ533308A (nl)
PL (2) PL218617B1 (nl)
PT (3) PT1889838E (nl)
SI (3) SI1864981T1 (nl)
TW (1) TWI305207B (nl)
WO (1) WO2001089457A2 (nl)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1699383A (zh) * 2000-03-08 2005-11-23 症变治疗公司 新的芳基果糖-1,6-二磷酸酶抑制剂
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US20110212054A1 (en) * 2000-05-25 2011-09-01 Glaxosmithkline Llc. Thrombopoietin mimetics
EP1370252A4 (en) * 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
US7659409B2 (en) 2002-03-19 2010-02-09 Mitsubishi Chemical Corporation 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
MY142390A (en) * 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
EP1556059A4 (en) * 2002-06-06 2010-06-30 Smithkline Beecham MIMETICS OF THROMBOPOIETINE
WO2004016264A1 (ja) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. トロンボポエチンレセプター活性化剤ならびにそれらの製造方法
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
WO2004096154A2 (en) * 2003-04-29 2004-11-11 Smithkline Beecham Corporation Methods for treating degenerative diseases/injuries
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US7753958B2 (en) * 2003-08-05 2010-07-13 Gordon Charles R Expandable intervertebral implant
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
RU2007110731A (ru) * 2004-09-23 2008-10-27 Редди Юс Терапевтикс Новые соединения пиримидина, способ их получения и содержащие их композиции
CA2583764C (en) 2004-10-25 2009-06-09 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
TWI351954B (en) 2004-12-08 2011-11-11 Nissan Chemical Ind Ltd Heterocyclic compounds and thrombopoietin receptor
TWI399368B (zh) 2004-12-14 2013-06-21 Nissan Chemical Ind Ltd Amide compounds and thrombopoietin receptor activators
TW200716580A (en) 2005-06-08 2007-05-01 Smithkline Beecham Corp (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
EP1904472A1 (en) 2005-07-15 2008-04-02 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
US7960425B2 (en) 2005-07-20 2011-06-14 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
WO2007044982A2 (en) * 2005-10-13 2007-04-19 Smithkline Beecham Corporation Methods for the preservation of platelet efficacy during storage
EP1947101A4 (en) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
EP2025671A4 (en) 2006-06-07 2011-04-06 Nissan Chemical Ind Ltd NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
JP2010511631A (ja) * 2006-12-01 2010-04-15 ステイテジックス・インコーポレイテッド トロンボポエチン擬態物
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
EP2152811A4 (en) * 2007-04-24 2011-03-16 Glaxosmithkline Llc NEW METHODS OF PREPARING HYDROXY-1-AZODEIVATES AS TPO MIMETIKA
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
MX2010003881A (es) * 2007-10-09 2010-07-28 Univ Pennsylvania El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano.
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009151862A1 (en) * 2008-05-15 2009-12-17 Smithkline Beecham Corporation Method of treatment
EP2348858A4 (en) * 2008-10-16 2013-06-12 Glaxosmithkline Llc PROCESS FOR THE TREATMENT OF THROMBOCYTOPENIA
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
KR101377778B1 (ko) * 2009-04-01 2014-03-27 플리바 흐르바츠카 디.오.오. 엘트롬보팩 및 엘트롬보팩 염의 다형체 및 이의 제조 방법
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
JP2012526137A (ja) * 2009-05-07 2012-10-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 血小板減少症を治療する方法
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
EP3127427B1 (en) * 2009-05-29 2020-01-08 Novartis Ag Methods of administration of thrombopoietin agonist compounds
CN101921232A (zh) * 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
CN102639314B (zh) 2009-12-01 2015-04-29 巴斯夫欧洲公司 基于聚氨酯的拉挤成型树脂体系
CN101805291A (zh) * 2010-04-26 2010-08-18 西北大学 1-(4-异丙苯基)-3-甲基-5-吡唑啉酮及其制备方法和应用
KR20130101519A (ko) 2010-09-01 2013-09-13 노파르티스 아게 Hdac 억제제와 혈소판감소증 약물의 조합물
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
WO2012121957A1 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
WO2012121958A2 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
US20140205582A1 (en) * 2011-07-06 2014-07-24 Cellerant Therapeutics, Inc. Megakaryocyte progenitor cells for production of platelets
SG2014012926A (en) * 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2755955A4 (en) 2011-09-13 2015-08-19 Glenmark Generics Ltd METHOD FOR PRODUCING SUBSTITUTED 3'-HYDRAZIN BIPHENYL-3-CARBOXYLIC ACID COMPOUNDS
WO2013049605A1 (en) 2011-09-28 2013-04-04 Assia Chemical Industries Ltd. Processes for the preparation of an intermediate in the synthesis of eltrombopag
CA2851788C (en) 2011-10-11 2022-11-29 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic bax
CN109293551A (zh) 2011-11-14 2019-02-01 利亘制药公司 与粒细胞集落刺激因子受体相关的方法和组合物
AU2012347534B2 (en) 2011-12-08 2018-01-25 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
BR112014018524B1 (pt) 2012-01-27 2023-03-28 Universite De Montreal Derivados de pirimido [4,5-b]indol, seu usos, composição farmaceutica, e método in vivo ou ex vivo para aumen-tar as células estaminais e/ou progenitoras
CN103360317B (zh) * 2012-04-11 2016-12-14 齐鲁制药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及用途
JP2015154715A (ja) * 2012-05-22 2015-08-27 国立大学法人旭川医科大学 ヒト単核球由来の新規血管再生細胞群及びその分化誘導法
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
WO2014150252A1 (en) 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
EP2799425A1 (en) 2013-04-29 2014-11-05 Esteve Química, S.A. Preparation process of an agonist of the thrombopoietin receptor
EP3041511B1 (en) 2013-09-02 2021-06-02 Hetero Research Foundation Compositions of eltrombopag
ITMI20131782A1 (it) * 2013-10-25 2015-04-26 Dipharma Francis Srl Procedimento per la preparazione di un agonista della trombopoietina
CN104628647A (zh) * 2013-11-12 2015-05-20 上海医药工业研究院 3-甲基-1-(3,4-二甲基苯基)-2-吡唑啉-5-酮的制备方法
CN104725318A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种爱曲伯帕的合成方法
WO2015111085A2 (en) 2014-01-27 2015-07-30 Cadila Healthcare Limited Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
CN103819406B (zh) * 2014-03-17 2015-04-08 苏州明锐医药科技有限公司 艾曲波帕的制备方法
CN111620870B (zh) 2014-04-22 2023-01-03 蒙特利尔大学 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用
CN105085276A (zh) * 2014-05-12 2015-11-25 上海医药工业研究院 艾曲波帕中间体及其制备方法和应用
CN105085287A (zh) * 2014-05-12 2015-11-25 上海医药工业研究院 3`-氨基-2`-羟基-[1,1`-联苯]-3-羧酸的制备方法
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
EP3188737A4 (en) 2014-09-05 2018-05-02 Hetero Research Foundation Crystalline form of eltrombopag free acid
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
SG11201703407UA (en) 2014-10-31 2017-05-30 Nissan Chemical Ind Ltd Ligand-binding fiber and cell culture substrate using said fiber
CN104829593B (zh) * 2015-03-26 2017-08-25 苏州福来兹检测科技有限公司 一种用于检测溶液中金属离子含量的有机化合物及其应用
WO2017042839A1 (en) 2015-09-08 2017-03-16 Actavis Group Ptc Ehf. Novel eltrombopag salt and preparation thereof
CN109070493B (zh) 2016-04-21 2021-06-25 巴斯夫欧洲公司 在聚氨酯的基础上制备拉挤制品的方法
EP3474834A1 (en) 2016-06-27 2019-05-01 The General Hospital Corporation Dba Massachusetts General Hospital Stimulating platelet generation by activating mitochondrial biogenesis
CN110382580B (zh) 2017-03-09 2022-04-19 巴斯夫欧洲公司 制备复合元件的聚氨酯制剂
CN107021928B (zh) * 2017-04-01 2022-11-18 常州制药厂有限公司 艾曲波帕新的中间体及其制备方法和应用
EP3395331B1 (en) 2017-04-26 2019-08-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising eltrombopag olamine
US11072586B2 (en) 2017-10-06 2021-07-27 Assia Chemical Industries Ltd. Solid state forms of eltrombopag choline
EP3409272B1 (en) 2018-03-07 2020-06-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
CN110467531B (zh) * 2018-05-09 2022-04-19 新发药业有限公司 一种3’-硝基-2’-羟基联苯-3-甲酸的制备方法
WO2019229572A1 (en) * 2018-06-01 2019-12-05 Aurobindo Pharma Ltd An improved process for the preparation of eltrombopag olamine and its intermediates
EP3604284B1 (en) 2018-08-02 2020-11-11 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline eltrombopag monoethanolamine salt form d
ES2815924T3 (es) 2018-08-02 2021-03-31 Fis Fabbrica Italiana Sintetici Spa Forma D1 cristalina altamente estable de la sal de monoetanolamina de eltrombopag
US20220071961A1 (en) * 2019-01-08 2022-03-10 Jiangsu Hengrui Medicine Co., Ltd. Dosing Regimen of Bicyclic Substituted Pyrazolone Azo Derivative
WO2021001044A1 (en) 2019-07-04 2021-01-07 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for the preparation of key intermediates for the synthesis of eltrombopag or salt thereof
JP7083793B2 (ja) * 2019-09-10 2022-06-13 Jfeケミカル株式会社 パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
US20210169854A1 (en) 2019-09-20 2021-06-10 Novartis Ag 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
CN114341113A (zh) * 2019-10-21 2022-04-12 广东东阳光药业有限公司 乙酰化艾曲波帕的新晶型及其制备方法
WO2021078076A1 (zh) * 2019-10-21 2021-04-29 广东东阳光药业有限公司 乙酰化艾曲波帕的新晶型及其制备方法
CA3160779A1 (en) 2019-12-06 2021-06-10 Synthon B.V. Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
US20230025286A1 (en) 2019-12-06 2023-01-26 Synthon B.V. Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
TR202014694A1 (tr) 2020-09-16 2022-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
WO2022201087A1 (en) 2021-03-25 2022-09-29 Novartis Ag 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
CN113336704B (zh) * 2021-06-11 2022-10-11 上海大学 丹参素衍生物及其制备方法和医药用途
CN114507186A (zh) * 2021-12-02 2022-05-17 天津力生制药股份有限公司 一种艾曲波帕的制备方法
WO2023111187A1 (en) 2021-12-15 2023-06-22 Galenicum Health, S.L.U Pharmaceutical compositions comprising eltrombopag

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (nl)
US851444A (en) * 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en) 1953-02-27 1957-07-24 Ciba Ltd Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) * 1954-10-26 1957-10-15 Ciba Ltd Azo-dyestuffs
DE1046220B (de) * 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en) 1956-07-23 1959-12-31 Bayer Ag ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) * 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) * 1965-04-09 1968-01-30 Interchem Corp Disazo pyrazolone pigments
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES523609A0 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FR2559483B1 (fr) * 1984-02-10 1986-12-05 Sandoz Sa Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en) * 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de) 1993-08-13 1995-02-15 Ciba-Geigy Ag Pigmentsalze
US5532202A (en) * 1993-12-28 1996-07-02 Dai Nippon Printing Co., Ltd. Thermal transfer sheet
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
CN1148408A (zh) 1994-02-14 1997-04-23 津莫吉尼蒂克斯公司 血细胞生成蛋白及其制造材料和方法
US5482546A (en) * 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) 1995-02-13 1998-05-05 Engelhard Corporation Pigment compositions
CN1315870C (zh) 1995-06-07 2007-05-16 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
US5622818A (en) * 1995-11-29 1997-04-22 Eastman Kodak Company Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) * 1996-05-30 1997-09-23 Engelhard Corporation Pigment compositions
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
GB9715830D0 (en) 1997-07-25 1997-10-01 Basf Ag Reactive dyes containing piperazine
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
JP2001521896A (ja) * 1997-10-31 2001-11-13 スミスクライン・ビーチャム・コーポレイション 新規な金属錯体
DE19851389A1 (de) * 1998-11-07 2000-05-11 Dystar Textilfarben Gmbh & Co Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
CA2380206A1 (en) 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Pharmaceutical compositions exhibiting thrombopoietin receptor agonism
EP1213965B1 (en) * 1999-09-10 2006-01-18 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1223944B1 (en) * 1999-09-24 2007-01-03 SmithKline Beecham Corporation Thrombopoietin mimetics
EP1228051A1 (en) 1999-11-05 2002-08-07 SmithKline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
EP1104674A1 (de) 1999-11-10 2001-06-06 Curacyte AG O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AR030273A1 (es) 2000-03-10 2003-08-20 Smithkline Beecham Corp Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina
US6214813B1 (en) * 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
US6436915B1 (en) * 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6642265B1 (en) * 2000-09-08 2003-11-04 Smithkline Beecham Corporation Thrombopoietin mimetics
US7241783B2 (en) 2000-12-19 2007-07-10 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2002057300A1 (en) 2000-12-21 2002-07-25 Smithkline Beecham Corporation Regulated activation of cell-membrane receptors by metal-chelating agonists
EP1361220A4 (en) 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
BR0206670A (pt) 2001-01-26 2004-02-25 Shionogi & Co Compostos halogenados que exibem agonismo para receptor de trombopoietina
EP1370252A4 (en) 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
JP3927001B2 (ja) 2001-06-15 2007-06-06 三菱化学株式会社 色素セット、インクセット並びに記録方法
US6560161B1 (en) * 2001-08-30 2003-05-06 Micron Technology, Inc. Synchronous flash memory command sequence
US7875728B2 (en) 2001-11-30 2011-01-25 Valocor Therapeutics, Inc. Hydrazonopyrazole derivatives and their use as therapeutics
WO2003074550A2 (en) 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
EP1556059A4 (en) 2002-06-06 2010-06-30 Smithkline Beecham MIMETICS OF THROMBOPOIETINE
TWI324593B (en) * 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
EP1581527A4 (en) 2002-12-13 2006-11-22 Smithkline Beecham Corp MIMETICS OF THROMBOPOIETINE
WO2004096154A2 (en) 2003-04-29 2004-11-11 Smithkline Beecham Corporation Methods for treating degenerative diseases/injuries
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
CA2583764C (en) * 2004-10-25 2009-06-09 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
WO2007044982A2 (en) * 2005-10-13 2007-04-19 Smithkline Beecham Corporation Methods for the preservation of platelet efficacy during storage
JP2010511631A (ja) * 2006-12-01 2010-04-15 ステイテジックス・インコーポレイテッド トロンボポエチン擬態物

Also Published As

Publication number Publication date
HU0800310D0 (en) 2008-07-28
CN100423721C (zh) 2008-10-08
US20040019190A1 (en) 2004-01-29
NO20025566L (no) 2003-01-22
JP3813875B2 (ja) 2006-08-23
ATE445606T1 (de) 2009-10-15
KR20070087255A (ko) 2007-08-27
AU2001274938C1 (en) 2006-09-28
AU2001274938B2 (en) 2006-01-19
EP1889838A1 (en) 2008-02-20
WO2001089457A3 (en) 2002-03-07
IL152988A (en) 2009-02-11
CN1444477A (zh) 2003-09-24
ATE374772T1 (de) 2007-10-15
US7674887B2 (en) 2010-03-09
CY2010012I1 (el) 2012-01-25
PL218617B1 (pl) 2015-01-30
ES2294000T3 (es) 2008-04-01
US7790704B2 (en) 2010-09-07
SI1864981T1 (sl) 2009-12-31
US7160870B2 (en) 2007-01-09
NO2020040I1 (no) 2020-11-19
US7439342B2 (en) 2008-10-21
AU7493801A (en) 2001-12-03
US20080214640A1 (en) 2008-09-04
ES2334843T3 (es) 2010-03-16
DE60139354D1 (de) 2009-09-03
PT1864981E (pt) 2009-08-31
FR10C0034I2 (fr) 2011-04-29
PT1294378E (pt) 2008-01-09
CY1107087T1 (el) 2012-01-25
JP2003534257A (ja) 2003-11-18
US20090176746A1 (en) 2009-07-09
NO324246B1 (no) 2007-09-17
CY1109435T1 (el) 2014-08-13
CN101343251B (zh) 2011-11-09
IL193619A0 (en) 2009-02-11
JP4546919B2 (ja) 2010-09-22
EP1889838B1 (en) 2009-10-14
LU91681I9 (nl) 2019-01-03
DE60140224D1 (de) 2009-11-26
EP1864981B1 (en) 2009-07-22
SI1294378T1 (sl) 2008-02-29
US20090155203A1 (en) 2009-06-18
SI1889838T1 (sl) 2010-02-26
US20080090787A1 (en) 2008-04-17
US20090176973A1 (en) 2009-07-09
KR20030060773A (ko) 2003-07-16
HUP0800710A2 (hu) 2003-10-28
EP1864981B8 (en) 2009-11-11
TWI305207B (en) 2009-01-11
US20070179192A1 (en) 2007-08-02
PL216528B1 (pl) 2014-04-30
DK1294378T3 (da) 2008-01-28
HU0800710D0 (en) 2009-01-28
EP1294378A2 (en) 2003-03-26
LU91681I2 (fr) 2010-06-21
CY1109730T1 (el) 2014-09-10
PL393259A1 (pl) 2011-07-04
JP2006137764A (ja) 2006-06-01
CN101343250A (zh) 2009-01-14
IL193618A0 (en) 2009-02-11
BR0111116A (pt) 2003-04-08
NZ533308A (en) 2005-10-28
HUP0302257A3 (en) 2007-03-28
BR0111116B1 (pt) 2013-10-08
IL193617A0 (en) 2009-02-11
AR030696A1 (es) 2003-09-03
FR10C0034I1 (nl) 2010-06-08
EP1294378A4 (en) 2004-01-28
KR100847172B1 (ko) 2008-07-17
US7452874B2 (en) 2008-11-18
HU230487B1 (hu) 2016-08-29
NO2010017I1 (no) 2010-09-20
US7648971B2 (en) 2010-01-19
US7335649B2 (en) 2008-02-26
KR100798568B1 (ko) 2008-01-28
HU227476B1 (en) 2011-07-28
HK1117825A1 (en) 2009-01-23
IL193617A (en) 2013-06-27
PT1889838E (pt) 2010-01-19
HUP0302257A2 (hu) 2003-10-28
MXPA02011621A (es) 2004-05-17
IL152988A0 (en) 2003-06-24
HK1056114A1 (zh) 2004-02-06
CY2010012I2 (el) 2020-05-29
EP1864981A1 (en) 2007-12-12
DK1864981T3 (da) 2009-09-07
WO2001089457A2 (en) 2001-11-29
US7332481B2 (en) 2008-02-19
CN101343251A (zh) 2009-01-14
NZ522474A (en) 2004-10-29
HK1113057A1 (en) 2008-09-19
CZ303176B6 (cs) 2012-05-16
EP1294378B1 (en) 2007-10-03
DK1889838T3 (da) 2010-02-08
DE60130760T2 (de) 2008-07-17
CA2411468C (en) 2008-04-15
US20070129338A1 (en) 2007-06-07
BRPI0111116B8 (pt) 2021-05-25
NO2010017I2 (no) 2012-06-11
US7473686B2 (en) 2009-01-06
MY136707A (en) 2008-11-28
DE60130760D1 (de) 2007-11-15
NO20025566D0 (no) 2002-11-20
HU230387B1 (hu) 2016-03-29
US20080090996A1 (en) 2008-04-17
ES2328179T3 (es) 2009-11-10
HK1055561A1 (en) 2004-01-16
CN101343250B (zh) 2011-09-21
PL359270A1 (en) 2004-08-23
CN101342169A (zh) 2009-01-14
AR066036A2 (es) 2009-07-22
DE122010000037I1 (de) 2011-01-27
CA2411468A1 (en) 2001-11-29
CZ20023852A3 (cs) 2003-05-14

Similar Documents

Publication Publication Date Title
BE2012C016I2 (nl)
FR10C0034I1 (nl)
BRPI0113085B8 (nl)
JP2001228781A5 (nl)
AR028236A3 (nl)
JP2002082282A5 (nl)
BRPI0113372A8 (nl)
JP2003528542A5 (nl)
JP2001281585A5 (nl)
CH694022C1 (nl)
JP2002133538A5 (nl)
JP2002126081A5 (nl)
JP2002085773A5 (nl)
JP2002169094A5 (nl)
JP2002010031A5 (nl)
IN192499B (nl)
CN3134731S (nl)
CN3136792S (nl)
CN3155832S (nl)
CN3145461S (nl)
AU2000274567A8 (nl)
CL2001002979A1 (nl)
CN3133795S (nl)
AU2000270908A8 (nl)
CN3155326S (nl)